Carlsmed is a commercial-stage medical technology company headquartered in Carlsbad, California, listed on Nasdaq under the ticker symbol CARL. The company specializes in AI-enabled, personalized solutions for spinal fusion surgery, operating at the intersection of artificial intelligence, 3D visualization, digital technologies, and medical device design.
The firm's principal product is the aprevo® personalized surgery platform, described as an end-to-end system that creates bespoke surgical plans and personalized spine fusion devices from patient-specific data. The platform holds FDA clearance for lumbar and cervical spinal fusion indications and has received Breakthrough Device designation.
Carlsmed's technology leverages proprietary digital processes to design and produce medical devices tailored to individual patient anatomy, moving away from one-size-fits-all implants in spine care. The company transitioned to public ownership in 2025.
